BiotechTube

Pemetrexed + Gemcitabine + Platinol

Phase 1/2Completed
1 views this week 0 watching💤 Quiet
Interest: 32/100
32
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Carcinoma, Transitional Cell

Conditions

Carcinoma, Transitional Cell

Trial Timeline

Dec 1, 2004 → Jul 1, 2006

NCT ID
NCT00101842

About Pemetrexed + Gemcitabine + Platinol

Pemetrexed + Gemcitabine + Platinol is a phase 1/2 stage product being developed by Eli Lilly for Carcinoma, Transitional Cell. The current trial status is completed. This product is registered under clinical trial identifier NCT00101842. Target conditions include Carcinoma, Transitional Cell.

What happened to similar drugs?

20 of 20 similar drugs in Carcinoma, Transitional Cell were approved

Approved (20) Terminated (1) Active (0)
✅Enfortumab VedotinAstellas PharmaApproved
✅Sonidegib Phosphate CapsulesSun PharmaceuticalApproved
✅LenvatinibEisaiApproved
✅Epirubicin + lipiodolJohnson & JohnsonApproved
✅ApatinibTabletsJiangsu Hengrui MedicineApproved
✅Gefitinib + DocetaxelAstraZenecaApproved
✅Olaparib + BevacizumabAstraZenecaApproved

Hype Score Breakdown

Clinical
9
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00101842Phase 1/2Completed

Competing Products

20 competing products in Carcinoma, Transitional Cell

See all competitors
ProductCompanyStageHype Score
CD40 agonist mitazalimab in combination with chemotherapyAlligator Bioscience ABPhase 1/2
26
AFM24 + SNK01AffimedPhase 1/2
14
NRC-2694-A + PaclitaxelNatco PharmaPhase 2
42
Sintilimab + Nab paclitaxel + CisplatinCSPC Pharmaceutical Group LimitedPhase 2
35
Autologous Mesothelin-specific TCR-T Cells + Cyclophosphamide + Fludarabine + BendamustineLonzaPhase 1
18
Pemetrexed + CarboplatinEli LillyPhase 3
40
PRGN-3005 UltraCAR-T cells + PRGN-3005 UltraCAR-T cellsPrecigenPhase 1
27
Cemiplimab + CetuximabEli LillyPhase 2
42
IMC-1121B (ramucirumab) + Oxaliplatin + Folinic acid + 5-FU + 5-FUEli LillyPhase 2
35
[203Pb]Pb-PSV359 + [212Pb]Pb-PSV359Perspective TherapeuticsPhase 1/2
33
CT-01 + EVEROLIMUSCaptor TherapeuticsPhase 1
26
BB-401Benitec BiopharmaPhase 2
25
Zentalis + GemzarZentalis PharmaceuticalsPhase 2
29
AzenosertibZentalis PharmaceuticalsPhase 2
25
6-Thio-2'-Deoxyguanosine + CemiplimabMAIA BiotechnologyPhase 2
32
6-Thio-2'-Deoxyguanosine + Cemiplimab + Docetaxel + Vinorelbine + Gemcitabine aloneMAIA BiotechnologyPhase 3
37
ateganosine + CadonilimabMAIA BiotechnologyPhase 1
26
gemcitabine + carboplatin + cisplatinEli LillyPhase 2
35
CetuximabEli LillyPhase 1
29
Ramucirumab + PaclitaxelEli LillyPhase 2
35